IP Verse

Beta-2 Microglobulin-Deficient Cells

EP2699593

UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
Application Number
EP12720040A
Filing Date
Apr 18, 2012
Status
Patent Maintained As Amended
Oct 2, 2020
Grant Date
Nov 4, 2020
External Links
Slate, Register

Biblio Summary

The patent EP2699593B2 was granted on Nov 4, 2020 by University Of Washington Through Its Center For Commercialization The patent is currently Patent Maintained As Amended.

Oppositions Filed by other Companies on the Patent

The table below shows 1 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

JAMES POOLE LIMITEDMay 30, 2018 N.A.

More Opposed Patents of University Of Washington Through Its Center For Commercialization

The table below shows the patents of University Of Washington Through Its Center For Commercialization that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP2838548Hla Class Ii Deficient Cells, Hla Class I Deficient Cells Capable Of Expressing Hla Class Ii Proteins, And Uses ThereofJul 19, 20232
EP2828218Methods Of Lowering The Error Rate Of Massively Parallel Dna Sequencing Using Duplex Consensus SequencingApr 7, 20213

Dossier Documents of the Patent

The documents dossier of the patent at EPO including all essential records in the patent's lifecycle, from filing to grant to oppositions.

  • Date

    Description

  • Get instant alerts for new documents